Inactive Instrument

Medifocus, Inc. Share Price Toronto S.E.

MFS.H

CA58470Q1019

Medifocus, Inc. is a Canada-based biotechnology company holding a portfolio of medical products encompassing thermotherapy systems. The Company develops and commercializes minimally invasive focused heat systems for the treatment of cancerous and benign tumors, and enlarged prostate, medically known as Benign Prostate Hyperplasia (BPH). It owns two focused heat technology platforms: The Endo-thermotherapy Platform and The Adaptive Phased Array (APA) Microwave Focusing Platform. The Endo-thermotherapy Platform from which Prolieve Thermodilatation System (Prolieve) was developed, can potentially be used to treat cancers in prostate, rectal, cervical and esophageal. The APA Microwave Focusing Platform directs precisely focused microwave energy at tumor center to induce shrinkage or eradication of tumors without undue harm to surrounding tissue. The Company's APA 1000 Breast Cancer Treatment System was developed from the APA technology platform.

Employees

Sector

More about the company

21/08/20	Medifocus Inc. Announces Resignation of Mirsad Jakubovic as Chief Financial Officer	CI
02/03/20	Medifocus Inc. Reports Earnings Results for the Third Quarter Ended December 31, 2019	CI
29/11/19	Medifocus Inc. Reports Earnings Results for the Second Quarter Ended September 30, 2019	CI
29/08/19	Medifocus Inc. Reports Earnings Results for the First Quarter Ended June 30, 2019	CI
30/07/19	Medifocus Inc. Reports Earnings Results for the Full Year Ended March 31, 2019	CI
28/02/19	Medifocus Inc. Reports Earnings Results for the Third Quarter Ended December 31, 2018	CI
03/01/19	Medifocus, Inc. Announces Global Market Expansion with Prolieve Performed and Reimbursed by Insurance Carriers in Hong Kong	CI
03/12/18	Medifocus, Inc. Announces FDA PMA Supplement Approval for New Labeling	CI
13/11/18	Medifocus Inc. Reports Earnings Results for the Second Quarter Ended September 30, 2018	CI
13/09/18	Medifocus Inc. Reports Unaudited Consolidated Earnings Results for the Quarter Ended June 30, 2018	CI
05/06/18	Medifocus, Inc. Announces Successful Completion of FDA Post Approval Study for the Prolieve (R) Thermodilatation(Tm) System	CI
09/01/18	Medifocus Inc. Enters into an Exclusive Distribution Agreement with Amos Gazit, Ltd to Market and Distribute Proven Prolieve® Thermodilatation System	CI
28/08/17	Medifocus, Inc. Reports Financial Results for the Fiscal Year Ended March 31, 2017	CI

08/09/20	Medifocus : IIROC Trading Halt - MFS	AQ
21/08/20	Medifocus Inc :. Announces Resignation of Chief Financial Officer	AQ
24/07/20	Medifocus Inc :. Announces Delayed Filing of Annual Disclosure Documents Pursuant to OSC Instrument 51-502	AQ
27/05/15	Medifocus : Announces Closes Equity Offering	PU
06/12/14	Medifocus : Technology Featured in a Mediaplanet Sponsored Insert in “USA Today” on Breast Cancer	PU

Manager	Title	Age	Since
William W. Jow CEO	Chief Executive Officer	68	30/09/2016
Douglas Liu IRC	Investor Relations Contact	61	-

Medifocus, Inc. Share Price Toronto S.E.

Stocks

MFS.H

CA58470Q1019

Latest news: Medifocus, Inc.

Press Releases: Medifocus, Inc.

Managers and Directors: Medifocus, Inc.

Company Profile